Ab&B Bio-Tech CO., LTD. JS (stock code: 02627, “AB&B BIO-TECH-B”) announced that its Board of Directors will convene on 31 March 2026. The agenda includes:

1. Review and approval of the audited consolidated financial results for the year ended 31 December 2025. 2. Consideration of a recommendation for a final dividend, if any. 3. Discussion of other customary matters.

The meeting will be chaired by Executive Director and Board Chairman Mr. An Youcai. The Board currently comprises nine members: three executive directors (Mr. An Youcai, Ms. Li Runxiang, Mr. He Yiming), three non-executive directors (Mr. Cheng Qianwen, Mr. Yu Jianlin, Mr. Du Mu) and three independent non-executive directors (Mr. Li Xiangming, Mr. Li Jianjun, Mr. Chen Chengbei).

The company intends to release its FY2025 audited results and any proposed final dividend following Board approval.